← feed

Is NCT02520752 results overdue?

Yes — results are overdue. Primary completion was 2017-01-30; the FDAAA-801 reporting deadline (2018-01-30) passed 3064 days ago and no results are posted on ClinicalTrials.gov.

A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors

NCT IDNCT02520752 ↗
SponsorNovartis Pharmaceuticals (INDUSTRY)
Public issuerNOVARTIS AG — NVS (CIK 0001114448) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2017-01-30 (ACTUAL)
Reporting deadline2018-01-30 (completion + 365d)
Days overdue3064
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 dde175a73f5c147d… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02520752. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →